{"prompt": "['Official Title: A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the', 'Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A', 'Patients With Inhibitors', 'NCT Number: NCT03191799', 'Document Date: Protocol Version 3: 09-March-2018']['PROTOCOL', 'TITLE:', 'A SINGLE-ARM, MULTICENTER PHASE IIIB', 'CLINICAL TRIAL TO EVALUATE THE SAFETY AND', 'TOLERABILITY OF PROPHYLACTIC EMICIZUMAB', 'IN HEMOPHILIA A PATIENTS WITH INHIBITORS', 'PROTOCOL NUMBER: MO39129', 'VERSION NUMBER:', '3', 'EUDRACT NUMBER:', '2016-004366-25', 'TEST PRODUCT:', 'Emicizumab (RO5534262)', 'MEDICAL MONITOR:', 'Dr.', 'MD, MBA', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'DATE FINAL:', 'Version 3: See electronic date stamp below', 'DATES AMENDED:', 'Version 1:31 January 2017', 'Version 2: 2 June 2017', \"Approver's Name\", 'PROTOGILL AMENDMENT APPROVAL', 'Date and Time (UTC)', 'Company Signatory', '09-Mar-2018 10:00:09', 'CONFIDENTIAL', 'This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel,', \"Switzerland. However, it may be implemented in individual countries by Roche's local affiliates, including\", 'Genentech, Inc. in the United States. The information contained in this document, especially any', 'unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is', 'provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your', 'staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this', 'information will not be disclosed to others without written authorization from Roche except to the extent', 'necessary to obtain informed consent from persons to whom the drug may be administered.', 'Emicizumab - F. Hoffmann-La Roche Ltd', 'Protocol MO39129, Version 3']['PROTOCOL AMENDMENT, VERSION 3:', 'RATIONALE', 'Additional safety and efficacy data are now available based on completed and', 'ongoing emicizumab clinical trials. In addition, inconsistencies within the protocol', 'have been corrected.', 'The changes and associated rationales are described below, along with the sections', 'of the protocol which have been impacted. Similar changes have been made to the', 'synopsis where applicable.', 'Change and Rationale', 'Sections Impacted', 'For consistency purposes, the study patient population of', 'Throughout protocol', 'interest is now referred to as patients with congenital', 'hemophilia A who have persistent inhibitors against FVIII', 'For consistency purposes, study drug, study medication and', 'Throughout protocol', 'investigational medicinal product (IMP) are now referred to as', '\"emicizumab\"', 'Background clinical data with emicizumab has been updated as', '1.2.2', 'new information is now available from additional clinical trials', '1.3', '(JP29574, BH29884, BH29992). This includes updated safety', '3.3.1', 'and efficacy information, an updated summary of anti-drug', '5.1.1', 'antibodies, and new guidance regarding peri-operative', 'management of patients receiving emicizumab. Specific safety', 'events (hypercoagulation, thromboembolic events and', 'thrombotic microangiopathy) have also been updated.', 'For consistency, thromboembolic events and thrombotic', '2 (Table 7)', 'microangiopathy (TMA), both adverse events of special', '3.1', 'interest, are now described as thromboembolic events,', '3.3', 'microangiopathic hemolytic anemia or TMA (e.g. hemolytic', 'uremic syndrome).', '4.5.6.8', '6.4', '9.4.1', 'Emicizumab - F. Hoffmann-La Roche Ltd', '2 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}